{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:59Z","timestamp":1760188859555},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T00:00:00Z","timestamp":1134086400000},"content-version":"vor","delay-in-days":4360,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective<\/jats:italic>. To define the natural history and outcome of eosinophilia\u2014myalgia syndrome (EMS) among a cohort of patients followed up at one center since the onset of their disease.<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>. Fifty\u2010seven patients with well\u2010characterized EMS were evaluated prospectively at a university hospital for 21\u201464 months (mean 36 months).<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>. Eighty\u2010eight percent of the patients continue to have symptomatic disease with &gt;3 clinical manifestations. Fatigue (91%), muscle cramping (75%), myalgia (70%), paresthesias with objectively demonstrated hypesthesias (62%), articular symptoms (54%), scleroderma\u2010like skin changes (44%), and proximal muscle weakness (40%) are the most common features of chronic EMS. New findings identified among this cohort include cognitive symptoms in 86% of the study group, tremor, and myoclonus.<\/jats:p><jats:p><jats:italic>Conclusion<\/jats:italic>. The recognition of new manifestations in EMS and ongoing clinical disease in 88% of patients highlights the chronic nature of this disorder. Continued prospective followup of a large patient base is warranted to further define the natural history of this newly recognized illness.<\/jats:p>","DOI":"10.1002\/art.1780370112","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T01:04:15Z","timestamp":1171501455000},"page":"84-87","source":"Crossref","is-referenced-by-count":7,"title":["Chronicity of The Eosinophilia\u2014Myalgia Syndrome"],"prefix":"10.1002","volume":"37","author":[{"given":"Lee D.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450130070029"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008093230601"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003293221301"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003293221302"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.263.11.1502"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199007000-00001"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-2-124"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90069-R"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.151.3.533"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.58.5.400"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91717-9"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0889-857X(21)00582-2","article-title":"L\u2010tryptophan\u2010associated eosinophilia\u2010myalgia syndrome: perspective of a new illness","volume":"17","author":"Kaufman LD","year":"1991","journal-title":"Rheum Dis Clin North Am"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.5.1282"},{"key":"e_1_2_1_15_2","unstructured":"SwygertLA BackEE AuerbachSB SewellLE FalkH: Eosinophilia\u2010myalgia syndrome: mortality data from the US national surveillance system.J Rheumatol(in press)"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199209000-00005"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.152.9.1889"},{"key":"e_1_2_1_18_2","first-page":"401","article-title":"Eosinophilia\u2010myalgia syndrome: follow\u2010up survey of patients in New York, 1990\u20131991","volume":"40","author":"Centers for Disease Control","year":"1991","journal-title":"MMWR"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-6-437"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.5.931"},{"issue":"5","key":"e_1_2_1_21_2","first-page":"R26","article-title":"18\u201324 month structured follow\u2010up of 210 patients with eosinophilia\u2010myalgia syndrome in 12 states (abstract)","volume":"36","author":"Hertzman P","year":"1993","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780370112","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780370112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:12:14Z","timestamp":1700698334000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780370112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/art.1780370112"],"URL":"https:\/\/doi.org\/10.1002\/art.1780370112","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}